AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05382819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT06378593
Drug: 3HP-2827
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3HP-2827 will be administered orally once daily in 28-day cycles.
Trial: NCT06535334
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy versus intraperitoneal chemotherapy in recurrent ovarian cancer
Trial: NCT05408208
Drug: Intralesional Injection of Methotrexate
RxNorm normalized name: methotrexate Injection
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque.~Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .
Trial: NCT04267809
Drug: Calcium and Vitamin D
RxNorm normalized name: Wellesse Calcium and Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium and Vitamin D tablets are registered and licensed in Singapore. For the study, we will be sourcing the Calcium and Vitamin D tablets from Singapore General Hospital Formulary.
Trial: NCT05179889
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 150 mg/m2 IV day 1, oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion\] 12 cycles per 2 weeks~mFOLFOX 6 \[Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 week
Trial: NCT05179889
Drug: mFOLFOX 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 weeks
Trial: NCT05632861
Drug: HuHuangLianzonggan capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuHuangLianzonggan capsule, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
Trial: NCT04772781
Drug: S (+) - Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: S (+) - Ibuprofen + placebo of Ibuflex®
Trial: NCT04772781
Drug: Ibuflex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuflex® + placebo of S (+) - Ibuprofen
Trial: NCT05652907
Drug: FSD201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT05652907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matched to FSD201 for oral administration.
Trial: NCT05308953
Drug: NVG-291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVG-291 is a drug injected under the skin (subcutaneous).
Trial: NCT05122182
Drug: Repagermanium Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-C chemokine receptor type 2 (CCR2) antagonist placebo
Trial: NCT05925647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0,9% infusion
Trial: NCT05057130
Drug: Doxorubicin, Cisplatin, Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT05057130
Drug: Doxorubicin, Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT06310733
Drug: LGG
RxNorm normalized name: LGG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take 10 mL of a suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution, supplied in a 10-mL dark bottle with a delivery cap.
Trial: NCT06310733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take 10 mL of an identical aqueous solution in appearance and taste but without LGG, supplied in a 10-mL dark bottle.
Trial: NCT04903158
Drug: test SHR3680 tablets
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receiving a single oral dose of SHR3680 tablets with 240mg (80mg\*3)
Trial: NCT04903158
Drug: reference SHR3680 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects receiving a single oral dose of SHR3680 tablets with 240mg (100mg\*2+20mg\*2).
Trial: NCT05244070
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05360147
Drug: Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues
Trial: NCT06171087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT05040425
Drug: Zi-Yin-Liang-Ge-San
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zi-Yin-Liang-Ge-San is composed of five herb ingredients, namely Rx. Scutellariae (Huang Qin), Rx. Glycyrrhizae (Gan Cao), Hb. Dendrobii (Shi Hu), Rx. Ophiopogonis (Mai Men Dong), and Hb. Menthae Haplocalycis (Bo He). It is orally administrated trice daily from the first day to the end of RT in the treatment group, aiming to prevent and manage the OM. ZYLGS is manufactured as a concentrated herbal extract, constituted 4 g per packet, and origin from pharmaceutical companies in Taiwan with good manufacturing practice (GMP).
Trial: NCT04634344
Drug: DZD2269
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of DZD2269 starting at 5 mg will be given on Cycle 0 and then followed by a wash-out period. Multiple doses of DZD2269 at the same dose level will be given once daily after the wash-out period.
Trial: NCT04863001
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all classes of antiarrhythmic drugs used in pediatrics cardiology unit assiut university
Trial: NCT05501821
Drug: KBA1412
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A, B, C
Trial: NCT04900428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluent solution
Trial: NCT05453227
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
Trial: NCT05251337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to either control group (nausea/vomiting or anxiety) will receive Wyndmere Naturals non-scented patches (i.e., blank hydrogel adhesive patches without essential oil infusion).
Trial: NCT04940273
Drug: Remifentanil Injection [Ultiva]
RxNorm normalized name: remifentanil Injection [Ultiva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
Trial: NCT05388279
Drug: JS012
RxNorm normalized name: Janus Kinase Inhibitor JS012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS012, i.v., q3w
Trial: NCT05541003
Drug: NBT-NM108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will consume NBT-NM108 in the form of 2 muffins daily.
Trial: NCT05780125
Drug: FibCLOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg of FibCLOT (rounded up to the nearest 2 or 3 grams) after protamine administration
Trial: NCT06369363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be assigned to 1 week of transdermal placebo patch.
Trial: NCT06369363
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be assigned to 1 week of transdermal estradiol (0.05 mg/day) patch.
Trial: NCT04939987
Drug: Oxycodone-Acetaminophen
RxNorm normalized name: acetaminophen / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid Control Cohort (One treatment selected)
Trial: NCT04939987
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental Cohort (Multimodal Approach)
Trial: NCT04939987
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Cohort (Multimodal Approach)
Trial: NCT00001030
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06092788
Drug: NTP42:KVA4 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of NTP42:KVA4 administered to healthy volunteers as a capsule
Trial: NCT06092788
Drug: NTP42:KVA4 Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of NTP42:KVA4 administered to healthy volunteers as a liquid
Trial: NCT06564298
Drug: SOX/XELOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and S-1 40mg/m2 po bid d1-14, every 21 days XELOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and Capecitabine 1000mg/m2 po bid d1-14, every 21 days
Trial: NCT05258266
Drug: ZX-101A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q.D., oral dosing
Trial: NCT06577077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 01 tablet in the morning and 01 tablet in the evening for 14 days
Trial: NCT06379997
Drug: Intra-articular infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (G2) will receive three intra-articular injections once per week for 3 weeks, without ultrasound guidance. The route of administration will be intra-articular via the posterior access route.
Trial: NCT05915247
Drug: HER-096
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a single dose via s.c. injection
Trial: NCT05915247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a single dose via s.c. injection
Trial: NCT04977427
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone inserted into lower punctum at the end of cataract surgery in order to control inflammation in the eye for the following 30 days after surgery.
Trial: NCT04977427
Drug: Prednisolone Acetate 1% Oph Susp
RxNorm normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Prednisolone taper following cataract surgery, QID for one week, followed by TID for one week, BID for one week, and QDaily for one week, then stop.
Trial: NCT05602649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be orally ingested
Trial: NCT05435729
Drug: DSP-9632P 27.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of DSP-9632P 27.5 mg
Trial: NCT05435729
Drug: DSP-9632P 82.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of DSP-9632P 82.5 mg
Trial: NCT05435729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for DSP-9632P
Trial: NCT05435729
Drug: DSP-9632P 55.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of DSP-9632P 55.0 mg
Trial: NCT05435729
Drug: Levodopa formulation
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of Levodopa formulation
Trial: NCT05858788
Drug: SAR441566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT06129604
Drug: TPST-1495
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will receive study treatment of 50mg TPST-1495 taken orally, once a day for 7 days prior and discontinued 3 days prior to scheduled surgery.
Trial: NCT04744649
Drug: XELOX or SOX
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S1 S-1: 40\~60mg Bid，d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA
Trial: NCT05225610
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml saline will be administered.
Trial: NCT06162949
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An antibiotic of macrolide group
Trial: NCT05702931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT06575127
Drug: FOLFOXIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as mentioned in Arm description
Trial: NCT05661474
Drug: Fitostimoline ® hydrogel group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of DFUs with Fitostimoline® hydrogel every day for 12 weeks.
Trial: NCT05661474
Drug: Saline gauze group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of DFUs with saline gauze every day for 12 weeks.
Trial: NCT05729360
Drug: GamCoviMab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 30 people will be randomized and receive the study drug (GamCoviMab) in a hospital setting (7 days of hospitalization).
Trial: NCT06578676
Drug: Ezetimibe/Rosuvastatin 10/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, QD
Trial: NCT06578676
Drug: Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, QD
Trial: NCT05028582
Drug: ARQ-154 Foam 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-154 Foam 0.3%
Trial: NCT05028582
Drug: ARQ-154 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT05314127
Drug: Fluorouracil Cream
RxNorm normalized name: Fluorouracil Cream
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5- Fluorouracil Cream 5% is applied once daily at night with a cotton tipped applicator
Trial: NCT05970510
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally once a day
Trial: NCT05891093
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate, goserelin acetate
Trial: NCT06247605
Drug: AL8326 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/tablet, Oral administration, once daily.
Trial: NCT06247605
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, once daily.
Trial: NCT05597241
Drug: apimostinel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-methyl-D-aspartate (NMDA) receptor modulator
Trial: NCT05597241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05082259
Drug: ASTX660
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTX660 will be supplied as capsules. Each hydroxylpropyl methylcellulose (HPMC) capsule contains either 30 mg or 90 mg of ASTX600 free-base equivalents, suitable for oral administration. Bottles are labelled with the capsule strength (ie, 30 mg or 90 mg) and are further distinguished by different-colored labels. Each bottle contains 14 capsules and an oxygen-absorber (not to be consumed).
Trial: NCT00136929
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05901935
Drug: Capecitabine tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO 1000 mg/m\^2, bid, D1-D14, Q3W
Trial: NCT05769738
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4ml of normal saline to be nebulized 3 times daily for 3 days
Trial: NCT05027451
Drug: IXT-m200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-methamphetamine chimeric monoclonal antibody (mAb)
Trial: NCT04947007
Drug: Isotonic solution
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, US guided suprascapulary and axillary block will be performed with isotonic solution
Trial: NCT04952805
Drug: MAD0004J08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.
Trial: NCT06557642
Drug: Entonox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minute inhalation using demand valve and mouthpiece
Trial: NCT05160623
Drug: Eyelid cleansing wipes
RxNorm normalized name: Systane Lid Wipes Eyelid Cleansing Wipes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EYECARE FORTE eyelid wipes (Dr. Fischer, Israel), used to clean the lids and lashes once daily
Trial: NCT06443957
Drug: Intranasal insulin-20U
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient was given 1ml of 20U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
Trial: NCT06529445
Drug: Median Dose VC004 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC004 Capsules qd per period, for two periods
Trial: NCT05872568
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The recommended dose range is 360 to 720mg,bid
Trial: NCT04802941
Drug: General practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General practice
Trial: NCT06167837
Drug: Normal Saline 10 mL Injection
RxNorm normalized name: normal saline 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 10 ml IV 30-60 minutes before EGD
Trial: NCT04547985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composed of filler material and encapsulated to appear identical to naltrexone.
Trial: NCT05748925
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: will be maintained on their medication
Trial: NCT03245528
Drug: LJPC-501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: angiotensin II
Trial: NCT04252625
Drug: Q-Urol
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-Urol is an over-the-counter herbal supplement manufactured by Farr Laboratories. It is a combination product composed of quercetin, pollen extract, bromelain, and papain.
Trial: NCT04252625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule
Trial: NCT04674813
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT04432155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% oxygen, and 70% nitrogen
Trial: NCT04974060
Drug: Remifentanil Injection
RxNorm normalized name: remifentanil Injection
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dilute 2mg Remifentanil with normal saline to 50 ml (40ug/ml) and continuously intravenous infused at the doses of 0.02, 0.04, 0.06, and 0.08 μg/kg/min for each lasting 30 minutes.
Trial: NCT05613738
Drug: 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
Trial: NCT05613738
Drug: 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
Trial: NCT05613738
Drug: 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
Trial: NCT05284318
Drug: Antibiotics treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After receiving intravenous antibiotics treatment for 2 weeks, and clinician determines whether to continue with any antibiotics.
Trial: NCT06575829
Drug: Algucosidase alfa 20 mg/kg once every 4 weeks instead of once every 2 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The interval of ERT with alglucosidase alfa will be extended from once every 2 weeks to once every 4 weeks. The dose of 20 mg/kg per infusion remains the same.
Trial: NCT06181084
Drug: LY3410738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06125652
Drug: anti Tim-3/CD123 CAR-T cell therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will receive prespecified dose of autologous CAR-T cells.